

January 17, 2024

CLINICAL MICROBIOLOGY

Discontinuation of Confirmatory ESBL Testing and Reporting by Shared Health Clinical Microbiology Laboratories

Date effective: January 17, 2024

Key Message:

- Starting January 17, 2024, Shared Health Clinical Microbiology Laboratories will cease confirmatory testing for, and reporting of extended-spectrum β -lactamases (ESBLs) for clinical isolates of *Escherichia coli*, *Klebsiella pneumoniae*, *Klebsiella oxytoca/Raoultella* spp., and *Proteus mirabilis*. Instead ertapenem and meropenem antimicrobial susceptibility testing results will be reported for all *Escherichia coli*, *Klebsiella pneumoniae*, *Klebsiella oxytoca/Raoultella* spp., and *Proteus mirabilis* with ceftriaxone-, ceftazidime-, or piperacillin/tazobactam non-susceptible (intermediate or resistant) phenotypes. ESBL-producing isolates of *Escherichia coli*, *Klebsiella pneumoniae*, *Klebsiella oxytoca/Raoultella* spp., and *Proteus mirabilis* have not been routinely reported to Infection Prevention and Control practitioners for >4 years.

Contact Information:

Dr. James Karlowsky, Medical Director, Clinical Microbiology, Shared Health, 204-237-2105, jkarlowsky@sharedhealthmb.ca

Joelle Carlson, Technical Director, Clinical Microbiology, Shared Health, 204-237-2073, jcarlson@sharedhealthmb.ca